Welcome to our dedicated page for Polypid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PolyPid Ltd. (Nasdaq: PYPD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer. PolyPid files annual reports on Form 20-F and frequent Form 6-K current reports, which provide detailed information on its clinical, regulatory, financial and corporate developments as a late-stage biopharma company.
Recent Form 6-K filings incorporate press releases on key milestones for D-PLEX100, PolyPid’s lead product candidate for the prevention of abdominal colorectal surgical site infections. These filings include reports of positive Phase 3 SHIELD II trial results, positive FDA pre-NDA meeting minutes supporting a New Drug Application submission, and the granting of Breakthrough Therapy designation. They also capture updates on the company’s regulatory strategy, such as the FDA’s agreement to a rolling NDA review.
PolyPid’s SEC reports further document manufacturing and quality milestones, including the successful completion of a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Health under the EU-Israel ACAA framework, which the company states confirms that its facility meets standards required for commercial production in the European market. Other 6-Ks address corporate governance matters, such as changes in board leadership, executive appointments, shareholder meeting outcomes and compensation policy approvals.
Financial information is regularly furnished through interim condensed consolidated financial statements and management’s discussion and analysis, attached as exhibits to Form 6-K. Additional filings describe capital-raising arrangements, including a Sales Agreement for the issuance and sale of ordinary shares and subsequent increases to the maximum aggregate offering price.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the main points of each document, helping readers quickly understand the significance of PolyPid’s 20-F annual reports, 6-K current reports and other registered offerings without reading every line of the underlying SEC text.
PolyPid, an Israeli biotechnology company established over five years ago, has filed Form D to report an exempt securities offering under Rule 506(b). The company has successfully completed a $26,692,799 offering, with all securities now sold to 20 investors.
The offering includes equity securities, along with options/warrants and their underlying securities. The company, which currently reports no revenues, maintains its principal operations at 18 Hasivim Street, Petach Tikva, Israel.
Key management includes:
- Four executive officers: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, and Jonny Missulawin
- Eight independent directors including Jacob Harel, Yechezkel Barenholz, and others
The offering involves no sales commissions or finder's fees, and none of the proceeds are designated for payments to executives or directors. The offering is not connected to any business combination transaction and is not intended to last more than one year.